The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism
Abstract
Context: BRAF mutations are common in papillary thyroid carcinomas (PTCs). By affecting the expression of genes critically related to the development and differentiation of thyroid cancer, they may influence the prognosis of these tumors. Objective: Our objective was to characterize the expression of thyroid-specific genes associated with BRAF mutation in PTCs. Design/Setting and Patients: We examined the expression of key markers of thyrocyte differentiation in 56 PTCs with BRAF mutations (BRAF-mut) and 37 with wild-type BRAF (BRAF-wt). Eight samples of normal thyroid tissue were analyzed as controls. Quantitative PCR was used to measure mRNA levels for the sodium/iodide symporter (NIS), apical iodide transporter (AIT-B), thyroglobulin (Tg), thyroperoxidase (TPO), TSH receptor (TSH-R), the transcription factor PAX8, and glucose transporter type 1 (Glut1). NIS protein expression and localization was also analyzed by immunohistochemistry. Results: mRNA levels for all thyroid-specific genes were reduced in all PTCs vs. normal thyroid tissues. NIS, AIT-B, Tg, and TPO expression was significantly lower in BRAF-mut tumors than in the BRAF-wt group. Glut-1 transcript levels were increased in all PTCs, and additional increases were noted in BRAF-mut tumors. In both tumor subsets, the NIS protein that was expressed was abnormally retained in the cytoplasm. Conclusion: BRAF V600E mutation in PTCs is associated with reduced expression of key genes involved in iodine metabolism. This effect may alter the effectiveness of diagnostic and/or therapeutic use of radioiodine in BRAF-mut PTCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,675
Self-citationBRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
The Sodium/Iodide Symporter (NIS): Characterization, Regulation, and Medical Significance
Dohán, O., De la Vieja, A., Paroder, V., Riedel, C., Artani, M., Reed, M., Ginter, C. S., & Carrasco, N. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0029 · Cited by 861
Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414
Riesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M. A., Nistal, M., & Santisteban, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01119 · Cited by 376
Lazar, V., Bidart, J.-M., Caillou, B., Mahé, C., Lacroix, L., Filetti, S., & Schlumberger, M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.9.5996 · Cited by 298
Self-citationSodium/iodide symporter: a key transport system in thyroid cancer cell metabolism
Filetti, S., Bidart, J., Arturi, F., Caillou, B., Russo, D., & Schlumberger, M. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410443 · Cited by 269
Self-citationBRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas
Puxeddu, E., Moretti, S., Elisei, R., Romei, C., Pascucci, R., Martinelli, M., Marino, C., Avenia, N., Rossi, E. D., Fadda, G., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031425 · Cited by 260
Self-citation
Cited by
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Molecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Xing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0727 · Cited by 529
Elisei, R., Ugolini, C., Viola, D., Lupi, C., Biagini, A., Giannini, R., Romei, C., Miccoli, P., Pinchera, A., & Basolo, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0607 · Cited by 528
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Cantwell-Dorris, E. R., O'Leary, J. J., & Sheils, O. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0799 · Cited by 459
Kim, T. H., Park, Y. J., Lim, J. A., Ahn, H. Y., Lee, E. K., Lee, Y. J., Kim, K. W., Hahn, S. K., Youn, Y. K., Kim, K. H., et al. (2012) · Cancer · doi:10.1002/cncr.26500 · Cited by 400
The clinical development of MEK inhibitors
Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 400
Chakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 391
Current practice in patients with differentiated thyroid cancer
Schlumberger, M., & Leboulleux, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00448-z · Cited by 342
The Na+/I− Symporter (NIS): Mechanism and Medical Impact
Portulano, C., Paroder-Belenitsky, M., & Carrasco, N. (2014) · Endocrine Reviews · doi:10.1210/er.2012-1036 · Cited by 319
Molecular Diagnostics and Predictors in Thyroid Cancer
Nikiforova, M. N., & Nikiforov, Y. E. (2009) · Thyroid · doi:10.1089/thy.2009.0240 · Cited by 309
Tufano, R. P., Teixeira, G. V., Bishop, J., Carson, K. A., & Xing, M. (2012) · Medicine · doi:10.1097/md.0b013e31826a9c71 · Cited by 302
Biondi, B., & Cooper, D. S. (2010) · Thyroid · doi:10.1089/thy.2009.0311 · Cited by 286
Molecular Diagnostics of Thyroid Tumors
Nikiforov, Y. E. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0664-rair.1 · Cited by 257
Oh, J. M., & Ahn, B.-C. (2021) · Theranostics · doi:10.7150/thno.57689 · Cited by 163
Romei, C., Ciampi, R., Faviana, P., Agate, L., Molinaro, E., Bottici, V., Basolo, F., Miccoli, P., Pacini, F., Pinchera, A., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0130 · Cited by 160
Godlewska, M., & Banga, P. J. (2019) · Biochimie · doi:10.1016/j.biochi.2019.02.003 · Cited by 60
Genetic mutations, molecular markers and future directions in research
Patel, K. N. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.437 · Cited by 6
Metadata
- Authors
- Durante, C., Puxeddu, E., Ferretti, E., Morisi, R., Moretti, S., Bruno, R., Barbi, F., Avenia, N., Scipioni, A., Verrienti, A., Tosi, E., Cavaliere, A., Gulino, A., Filetti, S., & Russo, D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-07-01
- Volume
- 92
- Issue
- 7
- Pages
- 2840-2843
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2097182421
- Cited by
- 397
- References
- 19
- FWCI
- 11.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.